

Index

- abdominal mass, 64
 ACCP guidelines, 24, 66, 67, 195, 211, 213, 214
 acenocoumarol, 202
 acquired thrombophilia, 220, 221
 severe syndromes, 172–174
 activated partial thromboplastin time (APTT), 109, 110, 124, 142
 activated protein C (APC), 90, 91, 92, 168
 acute lymphoblastic leukemia (ALL), 72, 80
 CSVt and, 73, 75
 risk factor for VTE, 208, 209
 acute myeloid leukemia, 73
 acute promyelocytic leukemia (APL), 73, 74
 acute respiratory distress syndrome (ARDS), 173
 ADAMTS13, 220
 adrenal vein thrombosis (AVT), 68
 afibrinogenemia, 169
 all transretinoic acid (ATRA), 73, 74
 alpha-2 antiplasmin, 182
 alteplase. *See* recombinant tPA
 AngioJet®, 190
 animal models, 107
 antiangiogenics, 74, 115
 antibiotics, 202
 anticoagulation, 6–9
 administration routes, 202
 CSVt, 40–41
 duration in HIT, 161
 HVT, 55
 management in cancer, 77–79
 monitoring, 145
 MVT, 53
 new anticoagulants, 201–204
 non-heparin, 161, 162
 pathways, 92–96
 PE treatment, 23–24
 PVT, 51
 RVT, 66, 67
 standard anticoagulants, 200–202
 thrombolysis, 186
 VTE, 136
 antiphospholipid antibodies (APA), 61, 97, 134, 173
 AIS and, 220, 221
 antiplatelet therapy, 225
 antithrombin (AT), 78, 80, 81, 90, 92, 93, 96, 114–115
 deficiency, 63, 134, 135, 168–169, 209
 neonatal hemostasis, 125
 replacement, 126
 antithrombotics, 40–41. *See also*
 anticoagulation, thrombolysis
 aortic arteriopathy, 224–225
 apixaban, 204
 aplastic anemia, 175
 argatroban, 161, 162, 202, 203
 arterial ischemic stroke (AIS), 33, 171, 195, 219, 224
 acquired thrombophilia and, 220, 221
 epidemiology, 219–220
 inherited thrombophilia and, 220, 221
 outcomes, 226
 subtypes, 221–226
 thrombolysis, 194, 226
 arterial thrombosis, 193–194
 asparaginase (Asp), 8, 79, 80, 209
 aspirin, 40, 62, 209, 214, 223, 226
 asthma, 208
 atherosclerosis, 210
 azathioprine, 223
 bacterial infections, 88–101
 AIS and, 222
 CVC-related, 208
 defense against, 88
 epidemiology of thrombosis, 96–100
 epidemiology of VTE, 97
 hemostasis and inflammation, 93
 inflammation and coagulation, 90–92
 invasion, 90
 recurrence of VTE, 101
 Virchow's triad and, 92
 VTE risk factor, 209
Bacteroides fragilis, 99
 bilateral cerebral arteriopathy, 223–224
 bimodal age pattern, 1, 17, 209
 bivalirudin, 161, 162, 202, 203
 blindness, 167, 168
 brain tumors, 74, 79
 Budd–Chiari syndrome, 47, 54–56, 99, 175
Burkholderia cepacia, 97, 101
 cancer, 4, 7, 18, 49, 77
 adrenal, 68
 anticoagulation management, 77–79
 neurological symptoms, 76
 solid tumors, 72
 thromboembolism and, 72, 75, 82
 thromboprophylaxis, 79–82
 thrombosis-associated, 74, 75
 thrombosis-specific, 72–73
 thrombus types, 74–77
 cardiac diseases, 3. *See also* congenital heart disease (CHD)
 cardiac surgery, 162, 209, 213, 214
 cardioembolism, 225–226
 cardiopulmonary bypass (CPB), 145, 159, 160
 care measures, 187
 CASCADE criteria, 221, 222, 223
 CAT assay, 149, 150, 151
 catastrophic antiphospholipid syndrome (CAPS), 173–174
 catheter-directed thrombolysis (CDT), 188–189, 192, 193
 ultrasound-directed, 189
 cavernous transformation, 50
 central venous catheter (CVC)
 patency, 184
 risk factor for VTE, 208
 central venous catheter (CVC)
 thrombosis, 2–3
 anticoagulation, 8
 hematology cancer, 73
 PE association, 18
 presentation, 4
 Ceprotin, 96, 167
 cerebral edema, 35
 cerebral sinovenous thrombosis (CSVt), 33, 34
 ALL patients, 73
 anatomy/pathophysiology, 34–35
 cancer and, 75–76
 clinical features, 36–37
 epidemiology, 33
 etiology and risk factors, 35–36
 imaging and diagnosis, 37–39
 infections and, 99
 management, 39–41
 outcomes, 41–42
 thrombolysis, 195
 cervical arteriopathy, 224–225

Index

- chest X-ray, 20
Chlamydia pneumoniae, 210
 chronic thromboembolic pulmonary hypertension (CTEPH), 26
 CIP assay, 147
 cirrhosis, 49, 148
 CloFAL assay, 146–147
 clot formation and lysis, 123, 126–128
 assays, 143–147, 148
 coagulation
 amplification/propagation, 124–125
 APL, 73
 biomarkers, 135
 initiation phase, 123–124
 phases of, 121
 regulation of, 125–126
 screening tests, 120
 coagulation proteins, 109–115
 functionality, 124
 plasma levels, 125
 coagulation system, 88
 bacterial interactions, 90–92
 infection and inflammation, 89
 overview, 88–90
 combined thrombophilias, 171
 compression stockings, 11, 12, 210
 compression ultrasound (CUS), 5
 computed tomography (CT), 37, 39, 50, 53
 computed tomography pulmonary angiography (CTPA), 21–22
 computed tomography venography (CTV), 5, 21, 37
 CSVST, 41
 congenital disorders of glycosylation (CDG), 170
 congenital fibrinogen deficiencies, 169
 congenital heart disease (CHD), 19, 21, 159, 160
 AIS and, 225
 risk factor for VTE, 209
 contraceptive pill, 18, 210
 contrast venography, 5
 cranial ultrasound, 37
 Crohn's disease, 151
 cyclophosphamide, 174
 cystic fibrosis, 97, 101

 dabigatran, 204
 dalteparin, 201
 D-dimer, 6, 20, 135
 AIS and, 221
 deep vein thrombosis (DVT), *See also*
 central venous catheter (CVC)
 thrombosis
 etiology and risk factors, 2–4
 infections and, 100
 outcomes, 9–12
 recurrence, 10
 thrombolysis, 192

 defibrotide, 76
 dengue hemorrhagic fever, 100
 desmoteplase, 182
 developmental hemostasis, 107–108, 115, 181, *See also* neonatal hemostasis
 coagulation proteins, 109–115
 platelet changes, 109, 110
 vascular endothelium, 108–109
 VTE risk and, 133–134
 direct thrombin inhibitors (DTI), 23, 161, 162, 201, 204
 disseminated intravascular coagulation (DIC), 73, 91, 97, 167, 172
 Doppler and imaging ultrasonography, 5, 21, 22
 CVST, 37
 HVT, 54
 PVT, 50
 RVT, 65, 67
 transcranial, 226
 dosing regimens, 188, 189, 203
 Drotrecogin®, 92
 dysfibrinogenemia, 169, 209

 echocardiography, 22
 ECLA assay, 148
 eculizumab, 175
 EkoSonic® system, 189
 elastic compression stockings (ECSs), 11, 12
 electrocardiography, 20
 embolectomy, 25
 encephalopathy, 37
 endogenous thrombin potential (ETP), 149, 150, 151, 152
 end-organ dysfunction, 97
 endothelial activation/injury, 221
 enoxaparin, 7, 9, 23, 81, 201, 202, 211
 enzyme-linked immunosorbent assays (ELISA), 160
 epilepsy, 42
Escherichia coli, 174
 ethnicity, 219
 euglobulin, 148
 extracorporeal membrane oxygenation (ECMO), 3, 145, 159, 160
 extracranial dissection, 224, 225
 extremity DVT, 5
 cancer and, 4
 presentation, 4
 prevalence, 1, 3
 radiology, 5–6
 extremity imaging, 22

 Fabry disease, 226
 factor V Leiden (FVL), 63, 151, 220
 factor VIII (FVIII), 49, 135, 221
 factor Xa inhibitors, 204
 femoral vein CVC, 3

 fibrin clot formation, 123, 126–127
 fibrin degradation product (FnDP), 148
 fibrinogen, 112, 113, 127
 congenital deficiencies, 169
 fibrinolysis, 123, 127–128, 135
 assays, 147–148
 developmental hemostasis, 181
 physiology, 180–181
 fibrinolytic system, 90, 94
 reference values, 182
 flow cytometry, 109
 focal neurological signs, 220
 focal cerebral arteriopathy (FCA), 222–223
 fondaparinux, 161, 162, 201, 202, 203, 204
 fresh frozen plasma (FFP), 78, 80, 81
 FTP assay, 152
 fungal infections, 100
Fusobacterium necrophorum, 98

 Geneva score, 20
 genome-wide association studies (GWAS), 136
 GFC assay, 148
 global assays, 142, 143, 150
 clot formation and lysis, 143–147, 148
 fibrinolysis measurement, 147–148
 thrombin generation, 148–152
 thrombin and plasmin generation, 152–153, 154
 glycosaminoglycans (GAGs), 108
 Gradenigo's syndrome, 99
 Gram-negative bacteria, 90, 97
 Gram-positive bacteria, 90, 97
 grey scale ultrasound, 65
 growth retardation, 50

 hematemeses, 50
 hematuria, 64
 hemolytic uremic syndrome (HUS), 91, 170, 173, 174
 hemorrhage, 10, *See also* intracranial hemorrhage (ICH)
 APML, 73
 CSVST, 35, 38, 40
 minimizing risk, 186
 risk of, 184–185, 202
 treatment, 187
 hemostasis, 88, *See also* neonatal hemostasis, developmental hemostasis
 endothelial role in, 95
 infection and inflammation, 93
 heparin, 55
 heparin re-exposure, 162
 heparin-bonded catheters, 3
 heparin-induced thrombocytopenia (HIT), 23, 159, 162, 201
 diagnosis, 158–160

Index

- epidemiology, 160
 management, 160–162
 pathophysiology, 158
 prevention, 162
 hepatic sinusoidal obstruction
 syndrome (SOS), 76–77
 hepatic vein thrombosis (HVT), 47,
 54–56, 99
 hepatitis B, 100
 HIPA assay, 160
 HIT clinical scoring system, 158
 HIT Expert Probability (HEP) score,
 159
 HIV, 100, 210
 homocysteine, 220
 homocystinuria, 170
 horseshoe crab, 88
 human plasma proteome, 110
 human recombinant tPA, 25
 hypercoagulable state, 36
 hypertension, 64, 67
 portal, 48, 51
 hypothermia, 146
 hypoxemia, 19

 idiopathic stroke, 226
 iliac vein compression (IVC), 4
 inflammation, 89, 90, 93
 AIS and, 222
 and coagulation, 90–92
 inherited thrombophilia (IT), 133, 134,
 209
 AIS and, 220, 221
 asymptomatic children, 136
 VTE recurrence, 135
 in-hospital VTE, 207
 prophylaxis, 210–214
 risk factors, 207–210, 211
 risk guidelines, 212
 risk stratification, 210
 intermittent pneumatic compression
 (IPC), 210
 international normalized ratio (INR),
 110, 202, 209
 international sensitivity index (ISI), 110
 interventional radiography (IR), 55
 intracranial hemorrhage (ICH), 40,
 185, 194, 195
 intravascular thrombosis, 183–184
 IVC filters, 9, 187
 cancer patients, 79
 PE treatment, 25

 jugular thrombophlebitis, 98

 kidney transplant, 65

 laboratory monitoring, 187
 Lemierre's syndrome, 98
 leukemia, 4

 lipoprotein(a), 220
 liver biopsy, 55
 liver disease, 145
 liver transplantation, 49, 55, 145
 low molecular weight heparin
 (LMWH), 6–9, 23, 24, 40, 201–202
 cancer patients, 77, 78, 80
 CVC-related VTE, 208
 prophylaxis, 211
 low-dose regimen, 188
 lymphoma, 73

 magnetic resonance angiography
 (MRA), 222
 magnetic resonance imaging (MRI),
 37–38, 39, 50, 219
 magnetic resonance pulmonary
 angiography (MRPA), 22
 magnetic resonance venography
 (MRV), 5, 34, 37–38
 Manco-Johnson instrument, 10
 mastoiditis, 99
 May-Thurner syndrome, 4
 megakaryocytes, 109, 120
 membranous nephritis, 61
 meningitis, 99
 meningococcemia, 167
 mesenteric venous thrombosis (MVT),
 52–54, 99
 meso-Rex bypass, 51, 52
 modified Villalta scale, 10
 monocyte-platelet aggregates (MPAs),
 109
 moyamoya disease, 223, 226
 mRNA, 112, 125
 MRSA, 100, 209
 musculoskeletal infections, 99

 neonatal CSVT, 33, 34, 35, 36, 39
 anticoagulation, 40
 cranial ultrasound, 37
 neuroprotection, 40
 neonatal hemostasis, 119, 120, 121, 128,
 See also developmental hemostasis
 coagulation regulation, 125–126
 fibrin clots, 126–127
 fibrinolysis, 127–128
 primary, 119–123
 secondary, 123–125
 neonatal RVT. *See* renal vein
 thrombosis (RVT)
 neonates, CVC risks, 3
 nephrotic syndrome, 18, 60, 61
 neuroprotection, 40
 neutrophil extracellular traps (NETs),
 91, 94
 NHA assay, 152
 nitric oxide (NO), 108
 non-heparin anticoagulation,
 161, 162

 obesity, 209
 OHP assay, 147
 osteomyelitis, 99, 101, 210
 osteopenia, 201
 osteoporosis, 7
 otitis media (OM), 99

 Paget-Schroetter syndrome, 4, 6
 pancreatitis, 52
 paroxysmal nocturnal hemoglobinuria
 (PNH), 174–175
 pelvic infections, 99
 percutaneous mechanical
 thrombectomy (PMT), 190–191
 PHACES syndrome, 223
 pharmacomechanical CDT (PCDT),
 190–191, 192
 phenprocoumon, 202
 plasma protein concentration, 113–114
 plasmin, 90
 synthesis, 180
 plasmin generation curve, 153
 plasminogen, 90, 127, 128, 181, 182
 adequate supply of, 186
 deficiency, 181
 plasminogen activator inhibitor
 (PAI-1), 181, 182
 platelets, 109, 110
 aggregation test, 160
 counts, 120
 functions, 109, 122, 123
 transfusion, 78
 pleuritic pain, 19
 polyethylene catheters, 3
 polyurethane catheters, 3
 portal biliopathy, 50, 51
 portal hypertension, 48, 51
 portal vein, 47, 48
 portal venous thrombosis, 47–52, 99
 post-thrombotic syndrome (PTS),
 10–12, 207
 thrombolysis, 191, 192
 thrombophilia and, 135
 post-translational modifications
 (PTM), 113
 primary hemostasis, 88, 94, 107, 119–123
 protein C, *See also* activated protein C
 (APC)
 concentrates, 96
 concentrations, 113, 126
 deficiency, 63, 134, 135, 166–168, 220
 neonatal form, 114
 system, 91, 93
 protein S, 63, 113, 134, 135, 151, 168
 prothrombin G20210, 63, 151, 220
 prothrombin time (PT), 110, 142
 prothrombotic condition, 2
 provoked DVT, 8
 proximate triggering event, 2
 P-selectin, 109

Index

- pseudoaneurysm, 224
 pulmonary angiography, 21–22
 pulmonary artery occlusion, 24
 pulmonary embolism (PE), 16
 cancer and, 77
 clinical signs, 19–20
 diagnosis, 20–22
 epidemiology, 16–17
 in-hospital patients, 207
 management approach, 23
 outcomes, 26
 pathophysiology, 18–19
 predisposing factors, 17–18
 resolution, 26
 thrombolysis, 193
 treatment, 22–26
 pulmonary vascular occlusion, 18
 purpura fulminans, 97, 100, 166–167, 172

 quality of life (QoL), 10

 radiology, 5–6
 radionuclide scintigraphy, 21
 recanalization rate, 38, 42
 recombinant human APC (rhAPC), 92
 recombinant tPA (rt-PA), 182, 183, 184, 192
 dosing, 185, 188, 189
 intravenous, 194, 195
 renal insufficiency/failure, 64, 67
 renal transplant, 61, 62, 64
 renal vein thrombosis (RVT), 60, 62, 99
 acute management, 66–67
 clinical presentation, 64–65
 epidemiology, 61
 long-term management, 67–68
 pathophysiology, 61–64
 radiology, 65–66
 reteplase, 182
 revascularization, 223
 reviparin, 7, 201
 right ventricular (RV) dysfunction, 24, 25, 26
 risk factors
 cancer-associated thrombosis, 74, 75
 in-hospital VTE, 207–210, 211
 risk guidelines, 212
 risk stratification, 210
 rivaroxaban, 204

 secondary hemostasis, 88, 93, 107, 123–125
 seizures, 36, 40
 selective Xa inhibitors, 23
 sepsis, 168, 208
 treatment, 92–96
 septic pylephlebitis, 49
 serotonin release assay (SRA), 160
 serpin, 181

 severe thrombophilias, 166, 172, 173
 acquired syndromes, 172–174
 fibrinogen deficiencies, 169
 genetic syndromes, 166–169
 metabolic disorders, 170–171
 neonates, 171
 PNH, 174–175
Shigella dysenteriae, 174
 short bowel syndrome, 3
 sickle cell disease, 18, 223, 226
 silicone catheters, 3
 small-vessel arteriopathy (SVA), 222
 SNPs, 136
 solid tumors, 72, 73–74
 splenectomy, 49, 52, 145
 splenic vein thrombosis (SPVT), 52, 99
 splenomegaly, 50, 52
 spontaneous DVT, 6
Staphylococcus aureus, 100, 209
 stem cell transplantation (SCT), 74, 76
 steroids, 223
 STP assay, 152, 153
 streptokinase, 181, 183
 stroke, 33, *See also* arterial ischemic stroke (AIS)
 superior sagittal sinus, 34
 SVC syndrome, 5
 systemic inflammatory response syndrome (SIRS), 173
 systemic lupus erythematosus (SLE), 8, 173
 systemic thrombolysis, 188, 193
 systemic varicella, 100

 tachypnea, 19
 Takayasu arteritis, 224
 tenecteplase, 182
 tertiary hemostasis, 107
 thoracic outlet syndrome, 4
 thrombectomy, 191
 PMT and PCDT, 190–191
 thrombin, 90, 91, 112
 as catalyst, 124
 fibrin clot formation, 126
 generation, 123
 thrombin generation assays (TGAs), 142, 148–152
 thrombin generation curve, 150, 153
 thrombocytopenia, 64, 78, 122, 123, *See also* heparin-induced thrombocytopenia (HIT)
 thromboelastography (TEG), 110, 142, 143–146
 instrumentation, 143–144
 thromboembolism (TE), *See also* venous thromboembolism (VTE)
 cancer and, 72–73, 74, 75, 82
 HIT and, 158, 161
 onset and recurrence, 134
 solid tumors, 73–74

 thrombophilia and, 134
 thrombolysis, 6, 9, 41, 180, 181, 182, 185, 195
 AIS, 194, 223, 226
 care measures, 186–187
 contraindications, 184–185
 HVT, 55
 indications for, 183–184
 PE treatment, 24–25, 26
 pharmacologic agents, 181–183
 suitability, 185
 therapy modes, 187–191
 thrombus location, 191–195
 thrombophilia, *See also* acquired thrombophilia, severe thrombophilias, inherited thrombophilia (IT)
 anticoagulation, 8
 cancer patients, 75
 combined, 171
 CSV and, 35, 36, 39, 41
 HVT, 54
 incident TE, 134
 MVT, 53
 PTS, 135
 PVT, 49
 RVT, 62, 68
 thromboprophylaxis, 79–82, 210–214
 thrombotic storm (TS), 173, 174
 thrombotic thrombocytopenia purpura (TTP), 91, 170, 171, 173, 174
 thrombus resolution, 9–10
 tinzaparin, 201
 tissue factor (TF), 89, 114
 expression, 123
 levels, 120
 neonatal hemostasis, 125, 126
 tissue factor pathway inhibitor (TFPI), 90, 93, 113, 169
 tissue plasminogen activator (tPA), 25, 26, 66, 67, 127, 181, 182, 183
 total parenteral nutrition (TPN)
 infusions, 3
 transcranial Doppler (TCD), 226
 trauma patients, 146, 209, 219
 Trellis system, 190
 tumor thrombosis, 74

 ultrasound-accelerated CDT, 189
 umbilical vein, 47, 48
 umbilical vein catheters (UVC), 48, 52
 unfractionated heparin (UFH), 6–9, 23, 24, 25, 160, 200–201
 cancer patients, 81
 prophylaxis, 214
 upper gastrointestinal bleeding, 50
 urokinase, 181, 183

 varicella, 100, 168, 222
 vascular endothelium, 95, 108–109

vascular occlusion, 18, 226	genome-wide perspective, 136	CVT-related VTE, 208
vena caval DVT, 5	health-care burden, 1	prophylaxis, 214
cancer and, 4	recurrence, 101, 133, 135	vitamin K-dependent factors,
prevalence, 1, 3	risk assessment, 136	110, 124
venography, 6, 22	risk factors, 133, 208–209	von Willebrand factor (VWF), 88
veno-occlusion, 47, 56, 76	thrombolysis, 193	V-Q scan, 21
venous infarcts, 38	treatment, 6–9, 136–137	
venous thromboembolism (VTE), 88,	viral infections, 100	warfarin, 80, 161, 167, 201, 202
133, <i>See also</i> in-hospital VTE,	ventricular assist devices (VAD),	prophylaxis, 214
pulmonary embolism (PE), deep	145, 160	Waterhouse–Friderichsen syndrome,
vein thrombosis (DVT)	viral infections, 100, 210	68
developmental hematosi and,	Virchow’s triad, 2, 18	Wells simplified score, 20
133–134	infection and, 92	white matter injury (WMI), 225
epidemiology, 1–2	vitamin K antagonists (VKA), 6–9, 23,	Wilms tumor, 75
epidemiology of infections, 96–100	24, 202	
fungal infections, 100	cancer patients, 77	zymogen, 96